To determine the percent of patients with refractory breast cancer where MP and RPMA based...

Key inclusion criteria:
- Received ≥ 4 weeks but ≤ 6 months of the last treatment
- PD on the last treatment or within 2 months of the last treatment dosing
- Progression of disease (PD) on ≥ 3 prior chemotherapeutic or biological regimens for...

Response rate (according to RECIST and tumor marker-specific response criteria).

This MP approach to selecting treatments benefitted 27% of patients (n=66) with a variety of...

Clinical benefit was defined by a the patient’s PFS ratio (PFS on MP selected therapy/PFS on prior therapy).

Current study was based on the methods and design of Von Hoff, et al., 2010 and added...

Refractory disease as defined below:
- ≥18 years of age
- Microdissection technology. Samples and controls...